Twist Bioscience (NASDAQ:TWST) Stock: Insider Paula Green Sells 294 Shares

Twist Bioscience Corporation (NASDAQ:TWST) SVP Paula Green sold 294 shares of the stock in a transaction on Monday, September 21st. The shares were sold at an average price of $165.49, for a total value of $48,654.06. Following the completion of the transaction, the senior vice president directly owned 116,720 shares in the company, valued at $19,315,992.80. This trade represents a 0.25% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Twist Bioscience Stock Up 16.1%

Shares of NASDAQ TWST opened at $184.03 on Friday. The company has a market capitalization of $11.54 billion, a price-to-earnings ratio of -82.90 and a beta of 2.22. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38. The business has a 50-day moving average of $125.11 and a two-hundred day moving average of $86.46. Twist Bioscience Corporation has a 1 year low of $23.30 and a 1 year high of $185.22.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Monday, August 3rd. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.05). Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.The business had revenue of $118.38 million for the quarter, compared to analyst estimates of $114.55 million. During the same period in the prior year, the company posted $0.33 earnings per share. The company’s revenue was up 23.2% compared to the same quarter last year. On average, analysts forecast that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Allworth Financial LP purchased a new stake in Twist Bioscience in the second quarter valued at approximately $62,000. Trifecta Capital Advisors LLC purchased a new position in shares of Twist Bioscience during the second quarter worth approximately $63,000. Western Wealth Management LLC acquired a new position in shares of Twist Bioscience in the 1st quarter valued at $31,000. Strs Ohio acquired a new position in shares of Twist Bioscience in the 1st quarter valued at $33,000. Finally, GAMMA Investing LLC raised its position in Twist Bioscience by 24.4% in the 2nd quarter. GAMMA Investing LLC now owns 943 shares of the company’s stock valued at $97,000 after purchasing an additional 185 shares during the last quarter.

Analyst Upgrades and Downgrades

TWST has been the topic of several recent analyst reports. Robert W. Baird increased their price target on shares of Twist Bioscience from $113.00 to $115.00 and gave the company an “outperform” rating in a research note on Tuesday, August 4th. Piper Sandler boosted their price objective on shares of Twist Bioscience from $85.00 to $115.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 5th. Canaccord Genuity Group upped their target price on shares of Twist Bioscience from $90.00 to $120.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. TD Cowen reaffirmed a “buy” rating on shares of Twist Bioscience in a research report on Monday, August 3rd. Finally, UBS Group initiated coverage on shares of Twist Bioscience in a research note on Wednesday, September 9th. They set a “neutral” rating and a $144.00 price target on the stock. Eight equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $103.00.

Key Twist Bioscience News

Here are the key news stories impacting Twist Bioscience this week:

• Positive Sentiment: Twist’s partnership with Eli Lilly’s TuneLab AI-driven drug-discovery platform, under which Twist will serve as a preferred antibody-characterization data provider, strengthens its exposure to pharmaceutical research and artificial-intelligence applications. Twist Bioscience Expands AI Drug Discovery Exposure With Lilly TuneLab Partnership
• Positive Sentiment: The company’s latest quarterly results showed revenue of $118.4 million, up 23.2% year over year, while full-year revenue guidance was raised. Those results provide fundamental support for the recent rally, although Twist remains unprofitable and missed the latest quarterly EPS estimate.
• Neutral Sentiment: TWST recently reached a new 12-month high, making the shares vulnerable to consolidation as investors lock in gains after the partnership-driven advance. Twist Bioscience Hits New 12-Month High
• Neutral Sentiment: Reported short interest was listed at zero shares as of September 24, implying no measurable short-covering pressure. Because the figure conflicts with the article’s description of a “significant increase,” investors should treat the data cautiously.
• Negative Sentiment: CEO Emily Leproust sold 1,687 shares, while SVP Paula Green and insider Dennis Cho sold 294 and 348 shares, respectively, at about $165.49. The filings state the sales were intended to cover tax withholding on vested equity awards, and each executive retained a substantial position, reducing—but not eliminating—the negative signal. SEC insider transaction filings
• Negative Sentiment: Quiver data shows 87 insider sales and no purchases over the past six months. Combined with ongoing losses and a stock price well above many analyst targets, the pattern may weigh on momentum and valuation-sensitive investors.

About Twist Bioscience

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA using a proprietary silicon-based platform. The company serves researchers and organizations in biotechnology, pharmaceutical development, agriculture, industrial chemicals and academic research.

Its products include synthetic genes, gene fragments, oligonucleotides and DNA libraries used in research, drug discovery, diagnostics development and other applications. Twist also provides next-generation sequencing tools and products, including target-enrichment and sample-preparation solutions, as well as synthetic biology services that support the design and testing of biological systems.

Twist was founded in 2013 and is headquartered in South San Francisco, California.